Abstract
Oestrogen receptor beta (ERβ) and epidermal growth factor receptor (EGFR) pathway can synergistically promote the proliferation, invasion, and metastasis of non-small-cell lung cancer (NSCLC) cells. ERβ has five subtypes, and the selective splicing of exon 8 in ERβ5 transcription translational phase makes its biological function different from other subtypes. The following study investigates whether ERβ5 interacts with EGFR pathway in lung cancer. Briefly, we found that the overexpression of ERβ5 and EGFR is associated with poor prognosis and decreased overall survival in NSCLC patients. Furthermore, the effects of ERβ5 and EGFR on cell biological behaviour were investigated in vitro. These results indicated that the combination of ERβ5 and EGF induces cell proliferation and invasion, while the combination of ERβ5 and Gefitinib (EGFR inhibitors, Gef) induces cell apoptosis and promotes cell mitosis in A549 cell line. In addition, the combination of ERβ5 and EGF increases the expression of ERβ5, EGFR, and p-ERK1/2 in lung cancer cells. To sum up, the obtained results suggest that ERβ5 and EGFR synergistically promote the progression of lung cancer by activating MEK/ERK signalling pathway, which provides a theoretical basis for m...Continue Reading
References
Jun 24, 1998·Biochemical and Biophysical Research Communications·J T MooreT M Willson
Jan 5, 2002·Molecular Endocrinology·Edward J FilardoKirby I Bland
Dec 18, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G SelvaggiG V Scagliotti
Aug 30, 2006·Proceedings of the National Academy of Sciences of the United States of America·Yuet-Kin LeungShuk-Mei Ho
Sep 27, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Maurizio Scaltriti, José Baselga
Feb 26, 2009·Journal of Carcinogenesis·Neelu Puri, Ravi Salgia
May 23, 2009·The Journal of Steroid Biochemistry and Molecular Biology·Pamela A HershbergerMark Nichols
Aug 21, 2009·The New England Journal of Medicine·Tony S MokMasahiro Fukuoka
Dec 17, 2009·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Hua ShenYong-Qian Shu
Dec 3, 2010·PloS One·Giulia PintonLaura Moro
Jan 31, 2012·The Lancet Oncology·Rafael RosellUNKNOWN Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia T
Mar 12, 2013·Endocrine·Zhaoguo LiuGuang Chen
May 8, 2013·International Journal of Cancer. Journal International Du Cancer·Hexiao TangSheng Zhou
May 16, 2013·American Journal of Respiratory Cell and Molecular Biology·Alexander V MisharinHarris Perlman
Jan 18, 2014·The European Respiratory Journal·Sabari VallathAdam Giangreco
Jun 25, 2014·Journal of Digestive Diseases·Bei Bei SunJing Yuan Fang
Oct 24, 2014·Cancer Science·Li-Han HsuShu-Huei Kao
Feb 6, 2015·CA: a Cancer Journal for Clinicians·Lindsey A TorreAhmedin Jemal
Jun 23, 2015·Scientific Reports·Zhijie WangJie Wang
Jul 22, 2015·Asian Pacific Journal of Tropical Medicine·Chong ShiShu-Wang Yin
Dec 17, 2015·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Yan-Hong WeiSheng Zhou
Apr 14, 2016·Toxicological Sciences : an Official Journal of the Society of Toxicology·Mary O HuffCarolyn M Klinge
Jun 14, 2016·Journal of Thoracic Disease·Hosein RafiemaneshAli Moini
Oct 21, 2016·Molecular Cancer Research : MCR·Masayoshi MiyawakiKenzo Soejima
Oct 25, 2016·Oncogene·C AmbrogioD Santamaría
Dec 8, 2016·Biomarkers in Medicine·Tieqiu LiHuahua Li
May 18, 2017·Biology Open·Jiezhen LiangXiaoying Zhou
Jun 12, 2017·Biochemistry. Biokhimii︠a︡·A M SurinV G Pinelis
Aug 5, 2017·Cancer Letters·Christy W S TongKenneth K W To
Aug 7, 2017·Oncology Letters·Tae-Gul LeeCheol Hyeon Kim